How Celeste is Transforming Women’s Health

AI-driven Precision Medicine for Safe and Effective Prescribing

Finding and prescribing the right medications for chronic conditions is often a complicated and slow process

Specialty medications often have intricate administration protocols and side effect profiles, requiring specialized handling, storage, and patient education to ensure safety and efficacy. Ensuring that patients and caregivers fully understand these protocols can be challenging. The complexity and side effects associated with specialty medications can lead to poor adherence, impacting treatment outcomes. 

Insurance coverage and payer policies greatly influence formulary alignment and medication selection. Navigating these policies to find covered alternatives that meet clinical needs is a constant challenge. 

Additionally, the rapid pace at which new specialty medications are approved and introduced to the market requires continuous learning and adaptation by specialty pharmacies to provide accurate therapeutic recommendations.

Celeste’s Solution

Celeste's ExactRx utilizes AI-driven precision medicine to transform patient data into tailored access and efficacy insights for specialty medications. Celeste creates personalized medication recommendations, ensuring patient safety and meeting more diverse patient needs.


Compared to a baseline of 70% in specialty pharmacies, Celeste’s solution results in ~95% MIDM medication adherence rate. Additionally, it saves ~20+ hours per week for prescribers and clinic staff.

How Femovate Helps

Celeste was awarded sponsorship through Guidea’s Femovate program for ‘23-’24. 

As part of the Femovate sponsorship, the digital health experts at Guidea will work with the team to refine the digital experience for provider’s using ExactRx. 

For more information about Celeste, visit and follow them on  LinkedIn

For more information on Femovate visit and follow us on LinkedIn

For interviews please contact Theresa Neil

Stay in touch

The application period for Femovate 2023-24 is now closed. Follow us on LinkedIn for updates and the selected startups announcement.